Clinical research sites are the ultimate end-users of the RTSM and many other eclinical technologies. So why is it that feedback from this key stakeholder is so often overlooked? And furthermore, what can we do to change that?
Recently 4G Clinical partnered with SCRS to host their first Site Advisory Group (SAG) for RTSM/IRT systems, where sites and sponsors gathered to discuss, among many other topics, how sponsors can become more site-centric.
We asked sites to share advice they would give a sponsor looking to be more site centric. Here's what they had to say:
1. Partner Early
Begin working with your sites as early as protocol design. One way to do this is by including site perspectives on your trial design steering committee. Sites can help you identify red flags early, saving you both time and money on protocol amendments down the line.
Watch Now: See how you can leverage the site selection
process to reduce future amendments.
2. Share Information Directly
Since most feedback is filtered through the CROs, the sites don’t know if what they are saying is making it back to you. Making sure that you follow up with sites directly can go a long way in strengthening your relationship.
It turns out sites can be very competitive. They want to know what you think of their performance and how it compares to your other sites. Try creating a quarterly report card to help your sites better understand their strengths and weaknesses, which will allow them to focus their efforts on improving areas that need it the most.
Watch Now: Hear why sites think an direct line of communication
between Sponsor and Site, outside of the CRO, is essential.
3. Continue Asking
It's no surprise that the best way to get feedback is to ask, so continue to keep that line of communication open. Sponsors can benefit from leveraging the experience sites have with specific trial types or particular patient populations at all stages of the trial.
For more on the site perspective, check out our Site Voices campaign, where we discuss the impact technology has on sites, as well as the overall challenges they face operationalizing trials.